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by decrease in other resources: € 1.4 million (total incremental budget) in the first year 
to € 3.7 million in the third year. ConClusions: The use of omalizumab to treat CSU 
with inadequate response to H1-antihistamines increases drug and drug-related costs, 
but this is partially offset by reduced disease-related costs in omalizumab recipients.
PSS14
Biologic treatmentS for moderate-Severe PSoriaSiS. What efficacy 
giveS you, coSt Should not take it aWay
Blanch C1, Prades M2, Lizán L2, Figueras M3
1Novartis Farmacéutica, Barcelona, Spain, 2Outcomes’10, Castellon, Spain, 3Novartis 
Farmaceutica S.A., Barcelona, Spain
introduCtion: Superiority of secukinumab, reported in two head to head (H2H) 
trials, provided new horizons to stablish standard of efficacy (clear skin or at least 
PASI 90) for biologic treatments (Bx) for patients with moderate-severe psoriasis. 
The budget impact of new Bx might preclude its use, preventing that patients can 
have objeCtives: To compare the cost-efficacy cost of Bx for moderate-severe psoria-
sis Methods: We built an average cost-efficacy model represented by a decision tree 
for a time horizon 2 years. Efficacy was measured as the proportion of patients achiev-
ing at least PASI 90. Patients considered non-responders at week 10-16 (as per SmPC 
recommendations) were switched to another Bx (consecutive treatment). Efficacy was 
drawn from published clinical trials (CT). For secukinumab and ustekinumab, efficacy 
data came from CLEAR study (H2H study comparing efficacy of both Bx). Highest 
efficacy according CT’s (week 24), was considered constant along the study period. 
Only pharmacologic costs were included in the analysis. Induction phase costs for 
the second Bx were ascribed to first Bx. Number Needed to Treat (NNT) and cost per 
patient achieving at least PASI 90, were calculated. results: Along 2 years, secuki-
numab monotherapy had the lowest NNT to achieve clear skin (NNT 1.39), followed 
by ustekinumab (2.44), infliximab (2.95), adalimumab (3.47) and etanercept (12.7). Out 
of the eleven most cost-efficacy consecutive treatments, secukinumab was present 
in 9, mainly as the first line Bx. ConClusions: Secukinumab had the lowest NNT to 
achieve at least PASI 90, with lower cost in the majority of alternatives analyzed. New 
standards of efficacy (cleasr skin or ar least PASI 90) are of paramount importance to 
achieve clear skin and better quality of life for patients. Economic analyses are also 
key for health care systems sustainability.
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objeCtives: Knowing the economic burden of pneumococcal infections on health-
care system is important for disease control and prevention. We aimed to esti-
mate the economic burden of pneumococcal infections in children < 5 years old in 
Turkey. Methods: Electronic medical records of children diagnosed with pneumo-
nia, meningitis, and acute otitis media (AOM) between January 2013 and April 2014 
were retrospectively evaluated. Children developed pneumonia 48 hours after hospi-
talization or hospitalized for ≥ 2 days in the last 90 days were excluded. Direct costs 
for inpatients (pneumonia and meningitis) included costs of healthcare services 
(hospitalization, visit, consultation, laboratory, radiology), drugs, and medical con-
sumables. Direct costs for outpatients (AOM) included hospital visit and prescribed 
drug costs. Indirect costs for all patients included parents’ productivity loss cost 
and their travel expenses to hospital. Costs were expressed as median (minimum-
maximum). results: Data of 131 children with meningitis (n= 10), pneumonia 
(n= 53), and AOM (n= 68) were analyzed. While the direct costs for meningitis, pneu-
monia, and AOM were € 3,346.38 (€ 591.54-€ 42,940.02), € 480.66 (€ 84.46-€ 18,627.56), 
and € 335.89 (€ 57.07-€ 2,765.58), respectively, their indirect costs were € 851.97 
(€ 415.55-€ 8,319.34), € 335.89 (€ 57.07-€ 2,765.58), and € 96.91 (€ 96.91-€ 310,406.23), 
respectively. The total cost was € 4,080.58 (€ 1007.1-€ 50,721.44) for meningitis, € 838.84 
(€ 141.53-€ 21,393.14) for pneumonia, and € 114.49 (€ 112.56-€ 310,438.64) for AOM. The 
economic burden will be € 9,258,836.02 for meningitis, € 190,317,696.88 for pneumo-
nia, and € 286,225,000 for AOM when the total costs per patient are adjusted to the 
annual average number of patients with meningitis, pneumonia, and AOM was 
2269; 226,882; and 2,500,000, respectively, in Turkey. Accordingly, the total economic 
burden of pneumococcal infections, excluding bacteremia, will be € 485,801,532.9 
in Turkey. ConClusions: Pneumococcal infections pose a significant burden on 
healthcare system due to its high direct and indirect costs. Thus, preventive actions, 
mainly vaccination, should be conducted regularly.
PSS16
comParaBle analySiS of PriceS for firSt Stage of dental 
imPlantation in ukraine
Got S, Barylyak A, Uhryn M, Fal O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
objeCtives: dental implantation significantly improves the quality of patients’ 
life. However, it is an expensive treatment. We conducted our research to study 
the best price-quality relationship for dental implants made of different materials: 
titanium, zirconia and sandblasted and acid etched titanium implants. The objective 
of the present study was to analyze and compare prices for first stage implanta-
tion depending on the material of dental implant in ten private dental clinics in 
Ukraine. Methods: We compared and analyzed the costs of first stage of dental 
implantation which was conducted in 10 private dental clinics in Ukraine during the 
period of 6 month (01 December 2014 - 31 May 2015). For that purpose we selected 
five leading manufacturers which produce dental implants. Prices for the tech-
nologies and materials were set by the Administration of Dental clinic. Statistical 
analysis of the costs was performed by a computer program x7 2009. results: The 
prices for implantation in ten private dental clinics were used for the comparative 
cost calculation of technologies with five different implants: one zirconia, one tita-
nium and three sandblasted and acid etched titanium implants. According to our 
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objeCtives: Acne vulgaris is one of the most common skin conditions, affecting 
primarily the adolescents. This disorder is characterized by an abnormal function-
ing of the pilosebaceous follicle causing different types of lesions. The objectives 
of the present study were to determine the prevalence of acne in adolescents in 
Europe and evaluate the impact of environmental and lifestyle factors on this con-
dition. Methods: A survey was conducted in a sample of individuals residing in 
Europe and aged 15 to 24. To ensure representativeness, the quota method was 
applied considering age, sex, residence location and occupational status of the 
reference person. Study participants were asked to complete a specifically devel-
oped questionnaire online, on two occasions separated by 6 months (not reported 
here). results: A total of 10 521 questionnaires were completed yielding an self-
reported average prevalence of acne of 57.8% in European adolescents. However, 
there were variations across countries, prevalence rates ranged from 42.2% in Poland 
to 73.5% in Czech Republic and Slovakia. Results from a multivariate regression 
demonstrated that heredity is a risk factor for developing acne whereas age appears 
to be protective. Indeed, in all selected countries, a decrease in the prevalence of 
acne associated with age was observed. Highest rates were reported in the age group 
15-17 and lowest in the age group 21-24. Among the lifestyle factors investigated, 
only tobacco and chocolate consumption were associated with acne. Indeed, the 
former seems to prevent acne whereas the latter was associated with a higher prob-
ability of experiencing the condition. ConClusions: The self-declared prevalence 
of acne is relatively high in European adolescents even if there are variations across 
countries. Heredity is the main identified risk factor for developing acne whereas 
age is negatively associated with the prevalence of this condition.
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objeCtives: The incidence of malignant melanoma has increased in the recent years 
and the role of ultraviolet radiation (UV) in the disease process is well established. 
Indeed, epidemiological data supported that sun exposure and, more particularly 
sunburns during childhood are associated with a higher risk of developing melanoma. 
The present study aims at evaluating sun exposure habits in the Mexican population 
and at assessing, in this population, the knowledge of risks associated with such expo-
sure. Methods: A total of 400 dermatologists practicing in the 11 most important 
cities of Mexico have been selected to participate in the study. Over a period of one 
week, each year from 2011 to 2014, they submitted questionnaires to every consulting 
patient whichever the reason for the consultation. These self-administered question-
naires were completed by the patients and aim at collecting data on sun exposure 
and prevention habits in the population as well as at evaluating knowledge about 
risks associated with sun exposure. results: A total of 11841 questionnaires were 
completed. The mean age of the study population was 49.3 years and respondents 
were predominantly women (sex ratio 2:1). The majority of individuals reported usu-
ally staying in the sun less than 2 hours a day but exposed themselves between 11 am 
and 4pm. However, most people reported using sunscreen when going to the beach 
and protecting themselves with tee-shirts and/or sunglasses. Sunscreen was pre-
dominantly bought in pharmacies but most people applied it only once day. Regarding 
knowledge on the risks associated with sun exposure, the study highlighted many 
gaps, particularly concerning differences between UVA and UVB and their health 
consequences. ConClusions: Enhancing knowledge about the risks associated with 
sun exposure is essential because a better und-erstanding of these risks is key for 
modifying people habits and improving outcomes.
SenSory SyStemS diSorderS – cost Studies
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objeCtives: A 3-year budget-impact model (BIM) was developed to estimate the 
impact on the Italian health care budget of introducing omalizumab for the treat-
ment of patients with chronic spontaneous urticaria (CSU) with inadequate response 
to H1-antihistamines (licensed dose). Methods: The model considered patients with 
CSU aged ≥ 12 years. The BIM was developed from the perspective of the Italian National 
Health Service (NHS). Only direct medical costs were considered: drug costs (omali-
zumab 300mg and H1-antihistamines), drug-related costs (administration, screening 
and monitoring) and disease-related costs (physician, emergency department and hos-
pitalisation). Omalizumab 300mg uptake was assumed to be 10.9% in the first year, 
17.5% in the second year and 28.6% in the third year (only treatments that would be 
substituted for omalizumab were included in the market treatment shares). Ex-factory 
prices (included all discounts) and National Tariffs were considered to estimate costs of 
drug and medical resource used, respectively. Costs were assessed in Euros (2015 val-
ues). results: The total number of patients treated in the first year was estimated to 
be 27,490, with 2,996 of those treated with omalizumab, increasing to a total of approxi-
mately 27,708 in the third year, with 7,925 receiving omalizumab. Considering only drug 
costs, the incremental budget impact of introducing omalizumab 300mg to the current 
market share was estimated to be € 4.4 million in the first year, increasing to € 11.7 mil-
lion in the third year. Considering total direct medical costs, it was possible to show 
that part of the incremental drug costs of introducing omalizumab 300mg was offset 
A418  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
in 10% of patients with vitreous haemorrhage average cost of which was 10% of 
616EUR/operation. It was assumed that surgical treatment (trabeculectomy, Seton 
operation or cyclophotocoagulation) was applied in 2% of increased ocular pres-
sure (IOP) patients average cost of which was 196EUR/operation. Pharmacologic 
treatment was assumed to be applied in 98% of the IOP patients cost of which 
was 4EUR/patient. Thus, overall cost of IOP was calculated as 8EUR. The cost of 
arterial thromboembolic events (282EUR) was taken from local sources. The total 
CoD was calculated as 5520EUR in patients treated with ranibizumab where the 
total cost excluding pharmaceutical was estimated as 590EUR (administration cost 
121EUR, monitoring cost 442EUR, adverse event cost 27EUR). ConClusions: In 
DME, the main part of total CoD was consisted of costs of the treatment, followed 
by monitoring costs.
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objeCtives: The introduction of treatment with inhibitors of Vascular Endothelial 
Growth Factor (VEGF) has made possible the treatment of the Retinal Vascular 
Diseases (RVD) for which there was limited therapeutic resources, or even none. 
The objective of this study was to estimate the average annual cost in Italy incurred 
by the National Health Service (NHS) as well as society due to RVD in which there 
is an overexpression of VEGF. Methods: We developed a probabilistic incidence-
based cost of illness model to estimate an aggregate measure of the economic 
burden associated to RVD-induced diseases in terms of direct and indirect costs. A 
systematic literature review was performed in order to extrapolate epidemiological 
and direct cost data for total or partial blindness patient in Italy. Indirect costs were 
calculated as social security costs analyzing a specific database of the National 
Institute of Social Security (INPS). Data were analyzed considering the total services 
provided and the mean cost for two types of benefits: disability pension and attend-
ance allowance. Furthermore, one-way and probabilistic sensitivity analysis with 
5,000 Monte Carlo simulations was performed in order to test the robustness of 
results. results: RVD with overexpression of VEGF was estimated to affect 0.84% 
of the Italian population (501.128). Direct costs analysis is under review while the 
annual indirect cost per patient for the disability pensions amount to € 3,454 for 
total blindness patient and € 3,157 for partial blindness. For attendance allowance 
was estimated an average cost of € 10,350 for total blindness € 2.397 for partial blind-
ness. ConClusions: This is the first study in which direct costs (incurred by NHS) 
and especially indirect costs (incurred by the Social Security System) were taken 
into account to estimate the overall burden associated with RVD with overexpres-
sion of VEGF in our Country.
PSS21
the coSt-of-diSeaSe (cod) in central retinal vein occluSion (crvo) in 
turkey: an exPert Panel aPProach for eStimation of coStS
Deger C1, Ozdemir O2, Eldem B3, Unlu N4, Alp MN5, Saatci AO6, Ozmert E7, Erdal E1, Sar C1, 
Asan S1, Sumer F1, Parali E1, Ozel O1
1Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, 2Yorum Consulting Ltd., Istanbul, Turkey, 
3Hacettepe University Faculty of Medicine, Ankara, Turkey, 4Ankara Training & Research Hospital, 
Ankara, Turkey, 5Ankara Numune Training & Research Hospital, Ankara, Turkey, 6Dokuz Eylul 
University, Faculty of Medicine, Izmir, Turkey, 7Ankara University, Faculty of Medicine, Ankara, 
Turkey
objeCtives: The objective of the study was to estimate the CoD in CRVO, in Turkish 
setting. Methods: An expert panel was held by participation of five ophthalmolo-
gists to discuss the disease management in CRVO. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring and adverse events. Two different treatment 
options (ranibizumab and dexamethasone) were studied. September-2014 local 
prices for medications and procedures were used as sources. September-2014 EUR 
currency rate (2.8671TL/EUR) was used. results: The frequency of treatments in a 
year were assumed as 8.8 and 2.0 and the numbers of outpatient visits in a year were 
accepted as 9 and 7 for ranibizumab and dexamethasone, respectively. Common 
adverse events were taken into account. The cost of cataract was accepted as equal 
to the cost of cataract removal operation which is 143EUR and the cost of retinal 
detachment was accepted as the average cost of surgical treatments as 368EUR. It 
was assumed that surgical treatment (trabeculectomy, Seton operation or cyclopho-
tocoagulation) was applied in 2% of increased ocular pressure (IOP) patients (average 
cost 183EUR/operation). Pharmacologic treatment was assumed to be applied in 98% 
of the IOP patients (4EUR/patient). Thus, overall cost of IOP was calculated as 7EUR. 
The total CoD was calculated as 3,823EUR per patients treated with ranibizumab, 
where the cost excluding pharmaceutical was determined as 138EUR. The CoD in 
patients treated with dexamethasone was estimated as 1,195EUR which is lower 
when compared to CoD in patients treated with ranibizumab. Total cost excluding 
pharmaceutical was calculated 240EUR for dexamethasone. ConClusions: In 
CRVO, the cost of treatment formed the major part of the total CoD when compared 
to monitoring, administration and adverse event costs.
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research the most accessible on costs and widespread technology of dental implan-
tation was conducted with zirconia or sandblasted/acid etched titanium implants 
despite their price is much higher than just titanium implants. Ukrainian patients 
pay out-of-pocket for dental implantation and the main task of stakeholders is to 
provide the most effective services. ConClusions: The most expensive was the 
implantation with sandblasted and acid etched titanium implants (p < 0,001) and 
zirconia implants (p < 0,5). Also we revealed that patients were highly motivated to 
pay for dental implantation in order to get the best esthetical result.
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Kreimendahl F
Institute of Empirical Health Economics, Burscheid, Germany
objeCtives: The dental benefit of sugar free gum is scientifically proven. Comparing 
Germany and Finland, both countries show similar health systems as well as dental 
health among the population, but the consumption of sugar free gum is much higher 
in Finland. This paper aims at extrapolating the consumption of sugar free gum in 
Germany to values of Finland to estimate the potential costs savings for the German 
health care system due to a decreased risk of caries by consuming more sugar free 
gum. Methods: Overall dental costs in Germany are identified and the share of 
expenditures due to caries is estimated. The dental benefit of the consumption of 
sugar free gum is quantified as a reduction of the relative risk of caries based on data 
from the literature. Extrapolating the chewing frequencies in Germany to finish values 
and combining these with the dental benefit of consuming sugar free gum allows esti-
mating the potential cost saving due to better dental health for both the statutory and 
private health insurance. results: The increase of the consumption of sugar free 
gum in Germany leads to a reduced risk for caries and better dental health. Potential 
cost saving amount to 240 M € for the statutory sector and 73 M € for the private 
sector. ConClusions: The overall state of dental health in Germany and Finland is 
similar and the countries show many commonalities with regard to the dental health 
system and overall dental health. By regularly consuming sugar free gum the risk 
of a caries can be reduced and cost savings up to 313 M € for Germany are possible.
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objeCtives: To analyse the direct and indirect medical costs in patients with dia-
betic macular oedema (DMO) or macular oedema secondary to retinal vein occlusion 
(MO-RVO). Methods: This was an observational, cross-sectional, multicenter study 
in adults diagnosed with DMO or MO-RVO in the last 6-12 months in one or both eyes. 
Health resource utilization (HRU) data were collected from diagnosis. Employment 
status of patients and the impact of the disease in their professional life were also 
assessed. Annual direct healthcare costs and indirect costs caused by morbidity were 
estimated by diagnostic group (€ , January 2014). Differences were assessed using 
Chi-square (or Fisher exact), Mann-Whitney or Kruskal-Wallis (Dunn contrast) tests. 
A multivariate regression analysis was used to predict the direct costs. results: 
The study included 448 subjects (DMO n= 255; MO-RVO n= 193). No differences in age, 
gender or time of observation were found. There was stabilization over time in visual 
acuity and also a reduction in the foveal thickness. There were differences in diagnos-
tic costs: MO-RVO= € 1,856 (95%CI:1,741-1,971), bilateral DMO= € 1,661 (1,512-1,810) and 
unilateral DMO= € 1,401 (1,307-1,494), p< 0.001; and treatment costs (p< 0.001). There 
were also differences in total medical costs: MO-RVO= € 4,639 (3,809-5,469), bilateral 
DMO= € 6,275 (4,889-7,660) and unilateral DMO= € 6,269 (4,209-8,329), p< 0.001. Costs due 
to permanent disability were greater in bilateral DMO (€ 11,712, 95% CI 2,395-21,029) 
than in unilateral DMO (€ 4,284, −516-9,085) and MO-RVO (€ 1,052; −553-2,657), p< 0.05. 
In the regression analysis, the variables associated with health costs were: number 
of hospitalization days and number of visits, time of observation, diagnosis and days 
off work. ConClusions: Patients with bilateral DMO have higher direct healthcare 
costs and indirect costs due to morbidity.
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objeCtives: The objective of the study was to estimate the CoD in DME, in Turkish 
setting. Methods: A panel by participation of seven ophthalmologists was held 
to discuss the disease management in DME. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring and adverse event. Cost of ranibizumab 
treatment was studied and January 2015 local prices for medications and proce-
dures were used as sources. January 2015 EUR currency rate (2.6785TL/EUR) was 
used. results: The frequency of treatments and outpatient visits were assumed 
as 7.4 for the first year, 4.0 for the second year, 2.9 for the third year and 1.0 for 
the following years for ranibizumab. Common adverse events were taken into 
account. The cost of cataract was accepted as equal to the cost of cataract removal 
operation which is 153EUR. It was assumed that vitroretinal surgery was applied 
